Keng Yoon Yeong

List of Publications by Year
in descending order

65	985	430442	454577
papers	citations	18 h-index	30 g-index

71	71	71	1272
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Current trends of benzothiazoles in drug discovery: a patent review (2015â€“2020). Expert Opinion on Therapeutic Patents, 2022, 32, 299-315.	2.4	21
2	Regio- and stereoselective synthesis of dispiropyrrolizidines through 1,3-dipolar cycloaddition reaction: Inhibition of KRAS expression. Journal of Molecular Structure, 2022, 1263, 133177.	1.8	1
3	Synthesis of novel carboxamide- and carbohydrazide-benzimidazoles as selective butyrylcholinesterase inhibitors. Molecular Diversity, 2022, 26, 2863-2876.	2.1	1
4	From Nucleic Acids to Drug Discovery: Nucleobases as Emerging Templates for Drug Candidates. Current Medicinal Chemistry, 2021, 28, 7076-7121.	1.2	6
5	Synthesis, Molecular Docking, and Biological Evaluation of Benzimidazole Derivatives as Selective Butyrylcholinesterase Inhibitors. Current Alzheimer Research, 2021, 17, 1177-1185.	0.7	4
6	Natural Sirtuin Modulators in Drug Discovery: A Review (2010 -2020). Current Medicinal Chemistry, 2021, 28, 7749-7766.	1.2	0
7	Benzimidazoles in Drug Discovery: A Patent Review. ChemMedChem, 2021, 16, 1861-1877.	1.6	40
8	Repurposing Antihypertensive Drugs for the Management of Alzheimerâ€™s Disease. Current Medicinal Chemistry, 2021, 28, 1716-1730.	1.2	6
9	A Patent Review on the Current Developments of Benzoxazoles in Drug Discovery. ChemMedChem, 2021, 16, 3237-3262.	1.6	38
10	Discovery of gamma-mangostin from Garcinia mangostana as a potent and selective natural SIRT2 inhibitor. Bioorganic Chemistry, 2020, 94, 103403.	2.0	21
11	Dualâ€TargetâÐDirected Ligand Displaying Selective Butyrylcholinesterase Inhibitory and Neurite Promoting Activities as a Potential Therapeutic for Alzheimer's Disease. ChemistrySelect, 2020, 5, 11229-11236.	0.7	2
12	Sirtuins and Their Implications in Neurodegenerative Diseases from a Drug Discovery Perspective. ACS Chemical Neuroscience, 2020, 11, 4073-4091.	1.7	21
13	Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool. Current Protein and Peptide Science, 2020, 21, 99-109.	0.7	42
14	Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimerâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2020, 19, 85-93.	0.8	49
15	Sirtuin inhibition and anti-cancer activities of ethyl 2-benzimidazole-5-carboxylate derivatives. MedChemComm, 2019, 10, 2140-2145.	3.5	14
16	In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2018, 26, 1511-1522.	1.4	27
17	Method validation in quantitative analysis of phase I and phase II metabolites of mitragynine in human urine using liquid chromatography-tandem mass spectrometry. Analytical Biochemistry, 2018, 543, 146-161.	1.1	15
18	Contrasting sirtuin and poly(<scp>ADP</scp>â€ribose)polymerase activities of selected 2,4,6â€trisubstituted benzimidazoles. Chemical Biology and Drug Design, 2018, 91, 213-219.	1.5	14

#	Article	IF	Citations
19	Anticancer activities of a benzimidazole compound through sirtuin inhibition in colorectal cancer. Future Medicinal Chemistry, 2018, 10, 2039-2057.	1.1	24
20	Synthesis and Crystal Structures of Ethyl 2-(4-Methoxyphenyl)-1H-benzo[d]imidazole-5-carboxylate Dihydrate and Its Building Block 4-Fluoro-3-nitrobenzoic Acid. Journal of Chemical Crystallography, 2018, 48, 170-176.	0.5	0
21	Antituberculosis agents bearing the 1,2-disubstituted benzimidazole scaffold. Medicinal Chemistry Research, 2017, 26, 770-778.	1.1	12
22	Ethyl nitrobenzoate: A novel scaffold for cholinesterase inhibition. Bioorganic Chemistry, 2017, 70, 27-33.	2.0	8
23	Novel Fluorescent Benzimidazoles: Synthesis, Characterization, Crystal Structure and Evaluation of Their Anticancer Properties. Letters in Organic Chemistry, 2017, 14, 33-38.	0.2	2
24	Structural Modifications of Benzimidazoles via Multiâ€Step Synthesis and Their Impact on Sirtuinâ€Inhibitory Activity. Archiv Der Pharmazie, 2016, 349, 1-8.	2.1	22
25	Potent sirtuin inhibition with 1,2,5-trisubstituted benzimidazoles. MedChemComm, 2016, 7, 2094-2099.	3.5	7
26	Sirtuin Inhibitors: An Overview from Medicinal Chemistry Perspective. Anti-Cancer Agents in Medicinal Chemistry, 2016, 16, 1003-1016.	0.9	16
27	Antimycobacterial activity and in silico study of highly functionalised dispiropyrrolidines. Medicinal Chemistry Research, 2015, 24, 818-828.	1.1	4
28	SIRT1 inhibition in pancreatic cancer models: Contrasting effects in vitro and in vivo. European Journal of Pharmacology, 2015, 757, 59-67.	1.7	38
29	Discovery of a potent and highly fluorescent sirtuin inhibitor. MedChemComm, 2015, 6, 1857-1863.	3.5	11
30	Synthesis and evaluation of antimycobacterial activity of new benzimidazole aminoesters. European Journal of Medicinal Chemistry, 2015, 93, 614-624.	2.6	38
31	Development of an enzyme linked immunosorbent assay for fast screening of cimaterol residues in various matrices. Asian Pacific Journal of Tropical Disease, 2014, 4, 244.	0.5	2
32	Synthesis and evaluation of novel benzimidazole derivatives as sirtuin inhibitors with antitumor activities. Bioorganic and Medicinal Chemistry, 2014, 22, 703-710.	1.4	48
33	A one-pot tandem synthesis of various 1,2-disubstituted benzimidazoles. Tetrahedron Letters, 2014, 55, 4697-4700.	0.7	13
34	Benzimidazoles as new scaffold of sirtuin inhibitors: Green synthesis, inÂvitro studies, molecular docking analysis and evaluation of their anti-cancer properties. European Journal of Medicinal Chemistry, 2014, 83, 448-454.	2.6	51
35	Synthesis, characterization, and molecular docking analysis of novel benzimidazole derivatives as cholinesterase inhibitors. Bioorganic Chemistry, 2013, 49, 33-39.	2.0	71
36	A facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines acting as antimycobacterial agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1383-1386.	1.0	43

#	Article	IF	Citations
37	Ethyl 2-[4-(dimethylamino)phenyl]-1-phenyl-1H-benzimidazole-5-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2013, 69, o886-o886.	0.2	2
38	Antituberculosis: Synthesis and Antimycobacterial Activity of Novel Benzimidazole Derivatives. BioMed Research International, 2013, 2013, 1-6.	0.9	16
39	Antimycobacterial Activity: Synthesis and Biological Evaluation of Novel Substituted (3E,5E)-3,5-diarylidene-1-phenethylpiperidine-4-one Derivatives. Letters in Drug Design and Discovery, 2013, 10, 471-476.	0.4	3
40	3-{5-Ethoxycarbonyl-1-[3-(2-oxopyrrolidin-1-yl)propyl]-1H-benzimidazol-2-yl}benzoic acid. Acta Crystallographica Section E: Structure Reports Online, 2013, 69, o304-o304.	0.2	0
41	Ethyl 2-[5-(4-fluorophenyl)pyridin-3-yl]-1-[3-(2-oxopyrrolidin-1-yl)propyl]-1H-benzimidazole-5-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2013, 69, o1013-o1014.	0.2	0
42	Synthesis of Highly Functionalised Dispiropyrrolidine Derivatives as Novel Acetylcholinesterase Inhibitors. Letters in Drug Design and Discovery, 2013, 11, 156-161.	0.4	2
43	Ethyl 2-(1,3-benzodioxol-5-yl)-1-[3-(1H-imidazol-1-yl)propyl]-1H-benzimidazole-5-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o247-o248.	0.2	1
44	Ethyl 2-(4-methoxyphenyl)-1-[3-(2-oxopyrrolidin-1-yl)propyl]-1H-benzimidazole-5-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o308-o309.	0.2	0
45	Ethyl 2-(4-bromophenyl)-1-phenyl-1H-benzimidazole-5-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o1683-o1683.	0.2	1
46	Ethyl 4-anilino-3-nitrobenzoate. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o1684-o1684.	0.2	2
47	Ethyl 1-phenyl-2-[4-(trifluoromethoxy)phenyl]-1H-benzimidazole-5-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o2715-o2716.	0.2	2
48	Ethyl 2-(4-hydroxy-3-methoxyphenyl)-1-[3-(2-oxopyrrolidin-1-yl)propyl]-1H-benzimidazole-5-carboxylate monohydrate. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o87-o88.	0.2	1
49	Ethyl 2-(4-nitrophenyl)-1-[3-(2-oxopyrrolidin-1-yl)propyl]-1H-benzimidazole-5-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o59-o59.	0.2	4
50	Ethyl 1-[3-(2-oxopyrrolidin-1-yl)propyl]-2-phenyl-1H-benzimidazole-5-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o251-o252.	0.2	1
51	Ethyl 2-(1,3-benzodioxol-5-yl)-1-[3-(2-oxopyrrolidin-1-yl)propyl]-1H-benzimidazole-5-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o471-o472.	0.2	1
52	Ethyl 2-(4-chlorophenyl)-1-phenyl-1H-benzimidazole-5-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o1863-o1863.	0.2	1
53	Ethyl 1-phenyl-2-[4-(trifluoromethyl)phenyl]-1H-benzimidazole-5-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o1864-o1865.	0.2	2
54	Ethyl 2-[4-(morpholin-4-yl)phenyl]-1-[3-(2-oxopyrrolidin-1-yl)propyl]-1H-1,3-benzimidazole-5-carboxylate monohydrate. Acta Crystallographica Section E: Structure Reports Online, 2012, 68, o2967-o2968.	0.2	1

#	Article	IF	Citations
55	Antimycobacterial activity: A facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4930-4933.	1.0	40
56	Antimycobacterial Agents: Synthesis and Biological Evaluation of Novel 4-(Substituted-phenyl)-6-methyl-2-oxo-N-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine- 5-carboxamide Derivatives by Using One-pot Multicomponent Method. Letters in Drug Design and Discovery, 2012, 9, 953-957.	0.4	0
57	Synthesis and discovery of novel hexacyclic cage compounds as inhibitors of acetylcholinesterase. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3997-4000.	1.0	21
58	Ethyl 1-[2-(morpholin-4-yl)ethyl]-2-[4-(trifluoromethyl)phenyl]-1H-benzimidazole-5-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o1215-o1215.	0.2	2
59	Ethyl 1-[2-(morpholin-4-yl)ethyl]-2-[4-(morpholin-4-yl)phenyl]-1H-1,3-benzimidazole-5-carboxylate. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o1772-o1772.	0.2	0
60	Ethyl 1-[3-(1H-imidazol-1-yl)propyl]-2-(4-chlorophenyl)-1H-benzo[d]imidazole-5-carboxylate dihydrate. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o2405-o2405.	0.2	7
61	Ethyl 4-[3-(1H-imidazol-1-yl)propylamino]-3-nitrobenzoate. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o2606-o2606.	0.2	1
62	Ethyl 2-(4-bromophenyl)-1-[3-(1H-imidazol-1-yl)propyl]-1H-benzimidazole-5-carboxylate monohydrate. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o3060-o3060.	0.2	1
63	7â€²-(4-Bromophenyl)-5â€²,6â€²,7â€²,7a'-tetrahydrodispiro[indan-2,5â€²-pyrrolo[1,2-c][1,3]thiazole-6â€²,2â€²â€²-indan]-1,3,1â€²â€² Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o3274-o3274.	0.2	3
64	4â€²-(4-Chlorophenyl)-1â€²-methyldispiro[indan-2,2â€²-pyrrolidine-3â€²,2â€²â€²-indan]-1,3,1â€²â€²-trione. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o2404-o2404.	0.2	4
65	Substituted spiro [2.3â€²] oxindolespiro [3.2â€³]-5,6-dimethoxy-indane-1â€³-one-pyrrolidine analogue as inhibitors of acetylcholinesterase. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7064-7066.	1.0	129